Jonathan Zalevsky - 30 Jun 2026 Form 4 Insider Report for NEKTAR THERAPEUTICS (NKTR)

Reporting relationship: Chief R&D Officer
Issuer ticker: NKTR
Reported as of: 30 Jun 2026
Net transaction value: -$397,670
SEC form: 4
Accepted by SEC: 02 Jul 2026, 19:06:41 UTC
Prior SEC filing: 17 Jun 2026
Next SEC filing: 24 Jul 2026
Source filing: View source filing
Reporting owner signature: Elizabeth Zhang, Attorney-in-Fact

Key filing fact

Jonathan Zalevsky filed Form 4 for NEKTAR THERAPEUTICS (NKTR) on 02 Jul 2026.

Key facts

This page summarizes Jonathan Zalevsky's Form 4 filing for NEKTAR THERAPEUTICS (NKTR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 02 Jul 2026, 19:06.

Change

Previous filing in this sequence was filed on 17 Jun 2026.
Current net transaction value: -$397,670.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001789857 Primary reporting owner

Zalevsky Jonathan

Relationship: Chief R&D Officer
Address: C/O NEKTAR THERAPEUTICS, 455 MISSION BAY BLVD SOUTH, SAN FRANCISCO
Signature: Elizabeth Zhang, Attorney-in-Fact
Signature date: 02 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NKTR transaction

Common Stock

Sale

Transaction value: $397,670
Shares: -5,681
Change %: -37%
Price: $70.00
Shares after: 9,756
Date: 30 Jun 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 1 footnote

Footnote F1

This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026.